There are currently 42 active clinical trials seeking participants for COVID19 research studies. The states with the highest number of trials for COVID19 participants are Florida, Texas, California and New York.
A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19
NCT04780685
Recruiting
This is a Phase II multi-center, double-blind, placebo-controlled, randomized study in Patients with moderate to severe lung injury due to COVID-19 or other potential viral and bacterial pathogens.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/07/2022
Locations: Providence Medical Foundation, Fullerton, California +1 locations
Conditions: Covid19
Register for Updates
Outcomes Mandate National Integration With Cannabis as Medicine
NCT03944447
Recruiting
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Gender:
All
Ages:
7 years and above
Trial Updated:
05/29/2022
Locations: OMNI Medical Services, Boca Raton, Florida +16 locations
Conditions: Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Register for Updates
COPD Circuit Exercise
NCT05395390
Recruiting
This study is being done to understand body's response to hybrid home-based and on-site rehabilitation program utilizing individually tailored exercises throughout a total of 18 sessions with 12 of them occurring onsite, in people with and without chronic respiratory diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and Obstructive Sleep Apnea (OSA) and in individuals recovered from COVID-19. Exercise training programs vary widely for people with COPD, OSA, and during prolonged reco... Read More
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/24/2022
Locations: Texas A&M University, College Station, Texas
Conditions: OSA, Covid19, Residual Symptoms of COVID 19, COPD
Register for Updates
Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19
NCT05045937
Recruiting
Ivermectin is currently being utilized by a number of physicians in the local area. My objective will be to enroll these patients at the time of their evaluation for COVID-19 infection and to follow their progress through their recovery.
Gender:
All
Ages:
Between 12 years and 110 years
Trial Updated:
04/25/2022
Locations: Patrick Robinson MD LLC, San Antonio, Florida
Conditions: Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Bronchitis
Register for Updates
Point-of-care Lung Ultrasound (POCUS)-Integrated Study of Admitted Patients With COVID-19
NCT05228717
Recruiting
This study seeks to define the ultrasound profile of patients with COVID-19, and document the progression of these ultrasound findings to develop prognostication and clinical decision instruments that can help guide management of patient with COVID-19. Primary aims include the development of ARDS, refractory hypoxemia, acute cardiac injury, pulmonary embolism, pneumothorax or death. Secondary aims include potential change in CT and plain film utilization given the use of POCUS, as well as emerge... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2022
Locations: UCLA-Ronald Reagan, Los Angeles, California +3 locations
Conditions: Lung Injury, ARDS, Acute Cardiac Event, Covid19, Ultrasound, Hypoxemia, Acute Respiratory Distress Syndrome
Register for Updates
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress
NCT04905836
Recruiting
This is a Phase 2 study to assess COVI-MSC in the setting of current standard of care in hospitalized subjects with RT-PCR confirmed SARS-CoV-2 (COVID-19) infection and acute respiratory distress / acute respiratory distress syndrome.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/07/2022
Locations: Teradan Clinical Trials LLC, Brandon, Florida +5 locations
Conditions: Covid19
Register for Updates
Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting
NCT04840459
Recruiting
No therapeutic agent is currently approved for the treatment of SARSCoV-2 infection. More importantly, no intervention is currently available to mitigate the progression of disease from mid/moderate to serve particularly in high risk patients. Recognizing this limitation and urgency of finding a treatment for COVID-19, the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergencyuse of the unapproved product bamlanivimab or casirivimab + imde... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
03/14/2022
Locations: DHR Health Institute for Research and Development, Edinburg, Texas +2 locations
Conditions: Covid19
Register for Updates
Outpatient Liquid Aspirin (OLA)
NCT04937088
Recruiting
The purpose of this study is to obtain reliable and interpretable data to inform future trials regarding our hypothesis that a novel, liquid aspirin formulation can mitigate COVID -19 associated coagulopathy (CAC) . The potential impact is to reduce COVID-19 related hospitalization within 30 days of diagnosis due to (1) pulmonary events including respiratory failure; (2) cardiac events including myocardial infarction and myocarditis (3) venous or arterial thrombotic events; (4) acute renal insuf... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
12/13/2021
Locations: Lsuhsc-No, New Orleans, Louisiana
Conditions: Covid19
Register for Updates
VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans
NCT04805931
Recruiting
This is a prospective, randomized controlled trial that will evaluate the effectiveness of two different targeted outreach interventions aimed at increasing Covid-19 vaccine uptake. Veterans who are eligible for COVID-19 vaccine receipt by priority status (based on institutional guidelines) will be identified. Veterans must be enrolled into Veterans Health Administration (VHA) care and meet age or illness institutional priority guidelines to be eligible. Veterans eligible for enrollment into the... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/25/2021
Locations: VA Puget Sound Health Care System, Seattle, Washington
Conditions: Covid19, Vaccine Refusal
Register for Updates
iCareDx PSS-1 Point-of-Care (POC) Assay for Detection of COVID-19
NCT04937595
Recruiting
Purpose of this clinical investigation is to establish the performance of the iCareDx PSS-1 RT PCR POC Testing Platform which is used to detect COVID-19 in symptomatic patients using the patients saliva. The study focuses on obtaining a minimum of 30 positive and 30 negative test for this study. Results will serve to establish the assay's performance. Symptomatic patients who are being tested for COVID-19 will be enrolled and consented into this study. If the patient consents, 2 saliva specimens... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/22/2021
Locations: Froedtert Health WAC, Wauwatosa, Wisconsin
Conditions: Covid19
Register for Updates
Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
NCT04363502
Recruiting
In this study Investigators propose to administer clazakizumab to patients with life-threatening COVID-19 infection manifest by pulmonary failure and a clinical picture consistent with a cytokine storm syndrome. This is a single-center randomized, double-blind, placebo-controlled trial in which 30 patients will be enrolled and randomly assigned in a 1:1 ratio to two study arms that will receive clazakizumab at a dose of 25 mg or placebo.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/10/2021
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Covid19
Register for Updates
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
NCT04445285
Recruiting
This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/26/2021
Locations: University of South Alabama, Mobile, Alabama
Conditions: Covid19
Register for Updates